Quia Pharma AB (publ) (QUIA.ST) Research

Quia Pharma AB specializes in the research, development, and commercialization of advanced drug delivery systems. Its core product, Uni-Qleaver®, utilizes a pioneering releasable pegylation technology. This innovative approach effectively mitigates common drawbacks and allows for the precise modulation of a drug's half-life. The company, established by Marek Kwiatkowski, is headquartered in Uppsala, Sweden.

Market snapshot

Symbol
QUIA.ST
Price
$0.00
Day change
-16.67%
Market cap
$1.3M
P/E ratio
-0.05x
52-week range
0.0005-0.03
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Aptahem AB (publ) (APTA.ST)
  • Chordate Medical Holding AB (publ) (CMH.ST)
  • Fluicell AB (publ) (FLUI.ST)
  • Gabather AB (publ) (GABA.ST)
  • LIDDS AB (publ) (LIDDS.ST)
  • ProstaLund AB (publ) (PLUN.ST)
  • S2Medical AB (publ) (S2M.ST)
  • Spermosens AB (SPERM.ST)

Open Quia Pharma AB (publ) (QUIA.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.